Lilly 3Q Revenues: $5.7 billion (+9%) 3Q Earnings: $556 million (-29%) YTD Revenues: $16.7 billion (+8%) YTD Earnings: $1.5 billion (-26%) Comments: Pharmaceutical revenue in the quarter grew 10%. New product revenue, composed of Trulicity, Basaglar, Taltz, Jardiance, Lartruvo, Cyramza, Olumiant and Portrazza, drove 14% volume growth and represented nearly 22% of total revenue. Trulicity revenue was $527.7 million, up 117%. Cyramza revenue was $196.0 million, up 23% Taltz sales were $151.3 ...